Patents by Inventor HENRIETTE O'GEEN

HENRIETTE O'GEEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Animal model of Angelman Syndrome
    Patent number: 11793177
    Abstract: The present invention concerns non-human animals with cells having a genome that is lacking the entire E3 ubiquitin ligase (Ube3a) gene (including all isoforms and alternative promoters). These animals are useful for modeling Angelman Syndrome. The invention also includes methods for assessing the effect of an agent, such as potential therapeutics, on an animal model by exposing the animal or cells, tissues, or organs isolated therefrom, to an agent of interest.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: October 24, 2023
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Edwin John Weeber, David J. Segal, Henriette O'Geen, Benjamin Pyles, Scott V. Dindot
  • SPLIT-ENZYME SYSTEM TO DETECT SPECIFIC DNA IN LIVING CELLS
    Publication number: 20230031446
    Abstract: The present invention provides methods and compositions for detecting genomic sequences of interest in living cells. In particular, the present disclosure provides a split-enzyme system that works with guide RNAs and RNA-guided nucleases to produce detectable luminescent signals exclusively in the presence of targeted genomic sequences.
    Type: Application
    Filed: November 23, 2020
    Publication date: February 2, 2023
    Inventors: David J. Segal, Nicholas Heath, Henriette O'Geen, Jacob Corn
  • TARGETABLE PROTEINS FOR EPIGENETIC MODIFICATION AND METHODS FOR USE THEREOF
    Publication number: 20190233805
    Abstract: Provided herein are fusion proteins comprising a catalytically inactive Cas9 domain and an effector domain. The fusion proteins of the present invention can be used to, for example, produce epigenetic modifications at target chromatin sites. Nucleic acids and expression vectors encoding the fusion proteins, as well as cells comprising the fusion proteins, are also provided herein.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 1, 2019
    Applicant: The Regents of the University of California
    Inventors: David J Segal, Henriette O'Geen, Joel P. Mackay, Peggy J. Farnham
  • ANIMAL MODEL OF ANGELMAN SYNDROME
    Publication number: 20190208752
    Abstract: The present invention concerns non-human animals with cells having a genome that is lacking the entire E3 ubiquitin ligase (Ube3a) gene (including all isoforms and alternative promoters). These animals are useful for modeling Angelman Syndrome. The invention also includes methods for assessing the effect of an agent, such as potential therapeutics, on an animal model by exposing the animal or cells, tissues, or organs isolated therefrom, to an agent of interest.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 11, 2019
    Inventors: EDWIN JOHN WEEBER, DAVID J. SEGAL, HENRIETTE O'GEEN, BENJAMIN PYLES, SCOTT V. DINDOT